- In February 2023, Mylab launched a new line of rapid tests aimed at diagnosing sexually transmitted diseases (STDs). These user-friendly tests can be stored at room temperature and are specifically designed for point-of-care settings in resource-limited areas. Additionally, they are valuable in blood banks for effectively detecting transfusion-transmissible infections (TTIs) in blood donors, thereby helping to minimize the risk of transmission
- In January 2023, Molbio Diagnostics introduced the Truenat HSV 1/2 test for detecting herpes simplex virus. This rapid test delivers results in just one hour, greatly enhancing the company's offerings in STD diagnostics. The swift turnaround time positions the Truenat test as a valuable tool for timely diagnosis and management of herpes infections
Frequently Asked Questions
The market is segmented based on Global Sexually Transmitted Diseases (STDs) Antimicrobial Medication Market Segmentation, By Drug Type (Antiviral / Antiretrovirals, Antibiotics, and Vaccines), Disease Type (Chlamydia, Gonorrhea, Syphilis, Genital herpes, HPV, and HIV / AIDS), End User (Hospital, Clinics, and Others) – Industry Trends and Forecast to 2032
.
The Global Sexually Transmitted Diseases Stds Antimicrobial Medication Market size was valued at USD 3.14 USD Billion in 2024.
The Global Sexually Transmitted Diseases Stds Antimicrobial Medication Market is projected to grow at a CAGR of 6.1% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
